Study of Dasatinib in Combination With Everolimus for Children and Young Adults With Gliomas Harboring Platelet-Derived Growth Factor Receptor (PDGFR) Alterations

University of Michigan Rogel Cancer Center

Status and phase: Terminated; Phase 2

Conditions: Glioma; Pontine Tumors; High Grade Glioma

Treatments: Drug: Dasatinib; Drug: Everolimus

Study type: Interventional

Funder types: Other

Identifiers

NCT03352427

UMCC 2017.042

HUM00123094 (Other Identifier)

Details and patient eligibility

About

This trial will evaluate the activity of dasatinib in combination with everolimus for children with gliomas harboring PDGFR alterations, including newly diagnosed high-grade glioma (HGG) or diffuse intrinsic pontine glioma (DIPG) after radiation (stratum A); and recurrent/progressive glioma (grade II-IV, including DIPG) (stratum B).

Enrollment: 3 patients

Sex: All

Ages: 1 to 50 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Histological confirmation of a newly diagnosed high-grade glioma or diffuse intrinsic pontine glioma (DIPG) (Stratum A)

• Histological confirmation (at diagnosis or relapse) of a recurrent or progressive grade II-IV glioma (including DIPG) (Stratum B)

• Participants must have a genomic (DNA and/or RNA) alteration (mutation, fusion, and/or amplification) involving PDGF-A, PDGF-B, PDGFR-A or PDGFR-B, as identified by tumor sequencing.

• Age at enrollment: Greater than 1 year and less than 50 years

• BSA (body surface area): BSA greater than 0.3 m2

• Karnofsky (Measure of performance for cancer patients where 100% represents perfect health) > 50% for patients > 16 years of age and Lansky (Measure of performance for pediatric cancer patients where 100% represents perfect health) > 50% for patients < 16 years of age. Neurologic deficits in patients with CNS tumors must have been relatively stable for a minimum of 7 days. Patients who are unable to walk because of paralysis, but who are able to sit in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.

• Adequate bone marrow function per protocol

• Adequate liver function per protocol

• Adequate renal and metabolic function per protocol

• Patients with known seizure disorder must have seizures adequately controlled with non- enzyme inducing antiepileptic medications

• No increase in steroid dose within the past 7 days

• Primary brain or spine tumor are eligible, including tumors with metastases, multiple lesions.

• Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy.

• Myelosuppressive chemotherapy: Must not have received within 3 weeks.

• Hematopoietic growth factors: At least 7 days since the completion of therapy with a growth factor, 14 days for long- acting.

• Biologic (anti-neoplastic agent): At least 7 days or 3 half-lives (whichever is longer) since the completion of therapy.

• Radiation therapy:

  • Stratum A: ≥ 2 weeks and </= to 12 weeks must have elapsed from radiation.
  • Stratum B: ≥ 2 weeks must have elapsed from focal radiation.

• > 3 weeks from major surgery. If recent craniotomy, adequate wound healing must be determined by neurosurgical team.

• Autologous Stem Cell Transplant or Rescue: No evidence of active graft vs. host disease and ≥ 4 weeks must have elapsed.

• All patients and/or a legal guardian must sign institutionally approved written informed consent and assent documents.

Exclusion criteria

• Patients who are breastfeeding, pregnant or refuse to use an effective form of birth control are excluded.
• Patients with uncontrolled infection are excluded.
• Patients receiving other anti-neoplastic agents are excluded.
• Patients requiring strong CYP3A4 or PGP inhibitors are excluded (per protocol)
• Patients requiring anticoagulation or with uncontrolled bleeding are excluded.
• Patients on steroids for symptom management must be on a stable dose for 7 days prior to start of treatment.
• Patients within 1 year of allogeneic stem cell transplant, patients with active GVHD or requiring immunosuppression are excluded.
• Previous hypersensitivity to rapamycin or rapamycin derivatives

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

3 participants in 1 patient group

Dasatinib+Everolimus

Experimental group

Description:

Dasatinib = 60 mg/m2 orally twice daily Everolimus = starting dose of 3.0 mg/m2, with titration of dosing after first cycle to keep everolimus trough level of 5-15 ug/ml Both agents will be taken daily for 28 day cycles. Cycles will be repeated every 28 days and patients may receive up to 24 cycles.

Treatment:

Drug: Dasatinib

Drug: Everolimus